Glenmede Trust’s Corcept Therapeutics CORT Stock Holding History

Glenmede Trust’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$267K	Buy	+2,337	New	+$142K	﹤0.01%	1128
2020 Q4	–	Sell	-904	Closed	-$15K	–	1435
2020 Q3	$15K	Buy	904 +36	+4%	+$574	﹤0.01%	1711
2020 Q2	$14K	Sell	868 -201	-19%	-$2.82K	﹤0.01%	1727
2020 Q1	$12K	Hold	1,069	–	–	﹤0.01%	2337
2019 Q4	$12K	Buy	1,069 +350	+49%	+$4.87K	﹤0.01%	2337
2019 Q3	$10K	Buy	719 +152	+27%	+$1.87K	﹤0.01%	2339
2019 Q2	$6K	Hold	567	–	–	﹤0.01%	2556
2019 Q1	$6K	Hold	567	–	–	﹤0.01%	2545
2018 Q4	$7K	Buy	+567	New	+$7.49K	﹤0.01%	2418
2017 Q4	–	Sell	-21,462	Closed	-$414K	–	2688
2017 Q3	$414K	Buy	+21,462	New	+$320K	﹤0.01%	957

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Glenmede Trust's CORT Position: Q1 2025 in Review

Glenmede Trust opened a new position in Corcept Therapeutics (CORT) in Q1 2025: 2,337 shares worth $267K. The stake represents ﹤0.01% of the portfolio and ranks #1128 among its holdings. This is a return to the name: Glenmede Trust previously reported a position in CORT as recently as Q3 2020.

Glenmede Trust first reported a position in CORT in Q3 2017 and has held it in 10 quarters since. The position peaked at $414K in Q3 2017. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

Glenmede Trust held 2,337 shares of Corcept Therapeutics worth $267K as of Q1 2025.
Corcept Therapeutics was a new Glenmede Trust position in Q1 2025.
Corcept Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2025, its #1128 holding.
Glenmede Trust first reported a position in Corcept Therapeutics in Q3 2017 and has held it in 10 quarters since.
Glenmede Trust's Corcept Therapeutics position peaked at $414K in Q3 2017.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.